Zobrazeno 1 - 10
of 61
pro vyhledávání: '"C Mulatero"'
Autor:
J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt
Publikováno v:
Health Technology Assessment, Vol 17, Iss 29 (2013)
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours. Objectives: The aim of this review was to assess the clinical effectivenes
Externí odkaz:
https://doaj.org/article/d8c3a18dc8e44c9d917853f4b9f9b2dc
Autor:
Leonel Hernandez-Aya, Pippa Corrie, M Sznol, Richard D. Carvajal, Namir J. Hassan, Jeff Evans, Middleton, Omid Hamid, C Mulatero, Alexander N. Shoushtari, Cheryl McAlpine, David Krige, Neil Steven, Joseph J. Sacco, N Little, J. R. Infante, Marlana Orloff, CM Coughlin, Takami Sato, Paul Nathan, Sandip Pravin Patel, A-M Hulstine
Publikováno v:
Journal for ImmunoTherapy of Cancer. 5
Autor:
Adam C.G. Thomas, D Fitzgerald, Catherine A. Harwood, Jason F. Lester, C Mulatero, S Subramanian, Nick Thatcher, Marianne Nicolson, S Compton, J. McPhelim, Raffaele Califano, Noor-ul-Ain Tariq, Rohit Lal
Publikováno v:
Drugs
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven b
Autor:
V. A. Papadmitrakopoulou, J. T. Beck, Neil Miller, S. Urva, Bruce E. Johnson, Ilona Pylvaenaeinen, Benjamin Besse, C. Mulatero, Peter Schmid, Katarina Petrovic, Sasa Dimitrijevic, Rebecca S. Heist, D.R. Camidge
Publikováno v:
Annals of Oncology. 25:505-511
Background This phase Ib study aimed to establish the feasible everolimus dose given with standard-dose etoposide plus cisplatin (EP) for extensive-stage small-cell lung cancer (SCLC). Patients and methods An adaptive Bayesian dose-escalation model a
Autor:
Andrew Elders, Pawana Sharma, C Mulatero, John Ford, Radha Todd, Robert Jones, Fiona Stewart, Pamela Royle, Graham Mowatt
Publikováno v:
European Journal of Cancer. 49:416-430
Aim To evaluate the evidence for denosumab for the treatment of bone metastases secondary to solid tumours and, using a network meta-analysis, indirectly compare denosumab with bisphosphonates and best supportive care. Data sources MEDLINE (1948 to A
Autor:
Andrew Lloyd, Chloe Tolley, C Mulatero, R Lal, John Brazier, Rob Arbuckle, Nancy Devlin, J Wells, K Jewitt
Publikováno v:
Value in Health. 18(7)
Autor:
Leif Håkansson, Meina Tang, Linda Wauk, C Mulatero, Malcolm R Ranson, John Wagstaff, Sandrine Marreaud, Lynn Broughton, Frederic Lehmann, Gordon C Jayson, D. Levitt, Manfred Herold, Alan Jackson, Jeremy A L Lawrance, Gerard Groenewegen, Jamal Zweit, Heinz Zwierzina
Publikováno v:
European Journal of Cancer. 41:555-563
We assessed the tolerability, safety, pharmacokinetics and dose-limiting toxicity (DLT) of the recombinant humanized IgG4 anti-vascular endothelial growth factor (VEGF) monoclonal antibody, HuMV833, in patients with advanced cancer. Cohorts of patien
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
British Journal of Cancer
A phase II study to evaluate the efficacy and toxicity of the combination of vinblastine, paclitaxel and cisplatin (PVC) in previously untreated patients with advanced transitional cell carcinoma. Chemotherapy naive patients with locally advanced or
Autor:
Graham Mowatt, Fiona Stewart, Andrew Elders, Rachel Todd, Pamela Royle, R Johnston, Pawana Sharma, C Mulatero, Ewen Cummins, John Ford, Robert Jones
Publikováno v:
Health Technology Assessment, Vol 17, Iss 29 (2013)
Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.The aim of this review was to assess the clinical effectiveness and cost-effectiveness